Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 23, 2024$4.96
P/E Ratio
N/A
Market Cap
$337.69M
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Overview
Trading Information
Company